In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 7-11 without prejudice to their presentation in another application, and amend claims 1-3 as follows:

1. (currently amended) A compound of formula (I)

wherein

 R^1 and R^2 are independently selected from phenyl, thienyl, and pyridyl, each of which is independently optionally substituted with one, two or three Z groups;

 $Z \ is \ selected from \ a \ C_{1-6} alkyl \ group, \ a \ C_{1-6} alky \ group, \ hydroxy, \ halo, \ trifluoromethyl, \ trifluoromethylthio, \ trifluoromethyl, \ nitro, \ amino, \ mono \ or \ di \ C_{1-3} alkylamino, \ mono \ or \ di \ C_{1-3} alkylamino, \ hono, \ hono, \ carbamoyl, \ carboxy, \ cyano, \ carbamoyl, \ mono \ or \ di \ C_{1-3} alkylamioyl, \ sulphamoyl, \ a \ cetyl, \ -O-CH_2-CH_2-O-attached \ at two \ adjacent \ carbons, \ and \ phenyl, \ optionally \ substituted \ with \ one \ or \ more \ of \ the \ following: \ a \ C_{1-6} alkyl \ group, \ trifluoromethoxy, \ halo, \ or \ -O-CH_2-CH_2-O- \ attached \ at two \ adjacent \ carbons;$

R4 and R5 are independently selected from:

a C_{1-6} alkyl group, optionally substituted with a C_{1-6} alkoxy group or trifluoromethoxy;

an (amino)C₁₋₄alkyl-group, wherein the amino is optionally substituted by one or more C₁₋₄alkyl groups;

a non-aromatic C_{3-45} carbocyclic group, optionally substituted with a C_{1-3} alkoxy C_{1-3} alkyl group;

a (C3-12cycloalkyl)C1-3alkyl-group;

a (CH₂),(phenyl), group, wherein r is 0,1,2,3 or 4, and wherein s is 1 when r is 0, otherwise s is 1 or 2, and wherein the phenyl groups are optionally independently substituted with one, two or three Z groups:

naphthyl:

anthracenvl;

a saturated 5- to 8-membered heterocyclic piperidine group containing one nitrogen and optionally containing one of the following: oxygen, sulphur or an additional nitrogen, wherein the heterocyclic piperidine group is optionally substituted by one or more C₁₋₃ alkyl groups or benzyl;

1-adamantylmethyl; and

a -(CH₂)_tHet group, wherein t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted by one or more $C_{1:3}$ alkyl groups, and wherein Het is an aromatic heterocycle optionally substituted by one, two or three groups selected from a $C_{1:6}$ alkyl group; a $C_{1:6}$ alkoxy group, trifluoromethoxy or halo or Het is a saturated 5 to 8 membered heterocyclic a piperidine group containing one nitrogen and optionally containing one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic piperidine group is optionally substituted by one or more $C_{1:3}$ alkyl groups, hydroxy or benzyl; and

wherein R4 may be H; and

wherein R⁴ and R⁵ taken together with the nitrogen atom to which they are attached form a saturated 5– to 8-membered heterocyclic piperidine group containing one nitrogen and optionally containing one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic piperidine group is optionally substituted with one or more C₁₋₃alkyl groups, hydroxy or benzyl;

X is CO or SO2; and

Y is absent or represents NH optionally substituted by a $C_{1,3}$ alkyl group; or a pharmaceutically acceptable salt, prodrug or solvate thereof; with the proviso that R^1 and R^2 are not both 4-methoxyphenyl and the proviso that when R^1 is phenyl and R^2 represents phenyl or 4-fluorophenyl, X is CO and Y is absent then the group NR^4R^5 is not methyl-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]amino, methylpiperazino, 2-[1-methyl-4-piperidinyl]ethylamino, or [2-[1-(phenylmethyl)-4-piperidinyl]ethyl]amino.

(currently amended) A compound of formula I as represented by formula (II)

wherein

 R^1 is phenyl, optionally substituted by one or more of the following: a $C_{1.6}$ alkyl group, trifluoromethyl, a $C_{1.6}$ alkoxy group, trifluoromethoxy, halo, or -O-CH₂-CH₂-O- attached at two adiacent carbons:

 R^2 is phenyl, optionally substituted by one or more of the following: a $C_{1.6}$ alkyl group, trifluoromethyl, a $C_{1.6}$ alkoxy group, trifluoromethoxy, halo, or -O-CH₂-CH₂-O- attached at two adjacent carbons; and

R⁶ is selected from 1-piperidinylamino, a C_{2-rev}eloalkylamino group, optionally substituted by C₁₋₃alkoxyC₁₋₃alkyl, pyridylamino, wherein the pyridyl ring is optionally substituted by one or more of the following: a C₁₋₄alkyl group; a C₁₋₄alkoxy group or trifluoromethoxy; a C₁₋₄alkylamino group, wherein the alkyl chain is optionally substituted by one or more of the following: a C₁₋₄alkoxy group, trifluoromethoxy or morpholino;

or a pharmaceutically acceptable salt , prodrug or solvate thereof;

with the provise that when R^4 is 4 methoxyphenyl and R^2 is 4 methoxyphenyl, then R^6 is not 2 (morpholino)ethyl.

3. (currently amended) A compound selected from:

4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)thiazole 2-carboxylic acid-cyclohexylamide;
5-(4-chlorophenyl) 4-(2,4-dichlorophenyl)thiazole 2-carboxylic acid-cyclohexylamide;
4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)thiazole-2-carboxylic acid-piperidin-1-

ylamide;

- 5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)thiazole-2-carboxylic acid piperidin-1-ylamide;
 - 4-(4-bromophenyl)-5-phenylthiazole-2-carboxylic acid cyclohexylamide:
 - 4-(4-bromophenyl)-5-phenylthiazole-2-carboxylic acid piperidin-1-ylamide;
 - 4.5 bis (4 chlorophenyl)thiazole 2 carboxylic acid cyclohexylamide:
 - 4.5-bis-(4-chlorophenyl)thiazole-2-carboxylic acid piperidin-1-ylamide;
 - 4 (4-methoxyphenyl) 5-phenylthiazole-2-carboxylic acid cyclohexylamide;
 - 4.5-bis (4-methoxyphenyl)thiazole-2-carboxylic acid cyclohexylamide:
 - 4.5-bis-(4-methoxyphenyl)thiazole-2-carboxylic acid piperidin-1-ylamide:
- 5-(7-bromo-2,3-dihydrobenzo[1,4]dioxin-6-yl) 4-phenylthiazole-2-carboxylic acid piperidin 1-ylamide:
- 4 (7-bromo 2,3-dihydrobenzo[1,4]dioxin 6-yl) 5-phenylthiazole 2-carboxylic acid pineridin 1-ylamide:
- 4,5-bis-(4-chlorophenyl)thiazole-2-carboxylie acid (2-methoxymethyleyelopentyl)-amide:
 - 4,5-bis-(4-chlorophenyl)thiazole-2-carboxylic acid pyridin-4-ylamide;
 - 4,5 bis (4-chlorophenyl)thiazole 2-carboxylic acid (2-ethoxyethyl)amide; and
- 4,5-bis-(4-chlorophenyl)thiazole-2-carboxylic acid (2-morpholin-4-yl-ethyl)amide and where applicable, optical isomers, tautomers, stereoisomers and racemates thereof as well as pharmaceutically acceptable salts and solvates thereof.
- (canceled).
- (previously presented) A pharmaceutical formulation comprising a compound of any one of claims 1 to 3 and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 6-11. (canceled).

REMARKS